Blaze Bioscience

Blaze Bioscience

  • Founded: 2010
  • Location: Seattle, WA
  • Employee range: 11 - 50
  • Clinical stage: Clin2/Clin3 (fast track)
  • Therapy area: Brain cancer (ODD)
  • Drug types: ONC
  • Lead product: Tozuleristide
  • Product link:
  • Funding: $5M Feb 2019; $16M B-1 Oct 2017; $9M B Dec 2013; $3.5M A Feb 2013; $5M A Jun 2012

job board

Short description:

Real-time cancer cell visualization for surgical applications

Drug notes:

Also Clin1 breast cancer, Clin1 skin cancer, Clin1 head & neck cancer, Clin0 lung cancer, self-administered Clin0 oncology; 4 undisclosed programs RD oncology, oncology diagnostics

Long description:

Blaze Bioscience is developing technology to facilitate surgery for cancer patients. Blaze’s mission is to make the detection, removal and treatment of all cancers sensitive, reliable and accessible. To achieve this, Blaze is using their Cystine-dense miniproteins (CDPs) discovery platform that searches for miniprotein structures with high specificity, ultrastability and scaffold diversity for binding a wide range of therapeutic targets. While CDPs are in research phase, Blaze is also pioneering their Tumor Paint Technology including their first product, BLZ-100, a drug that attaches to tumor tissue and fluoresces when a special light from the Canvas is shined on it. This enables surgeons to visualize the outer edges of a tumor as they operate.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy